Member Info for ABftse

Hopefully not long now. Get a move on 201.

I think Valirx are one of the best at communicating. Regular RNS updates, video conferences, Q&As and the option to email the CEO directly.

@rhubarbmk2
We don't own TheoremRx.

Ken talks TheoremRx. Well spotted!
May 4, 9-10 am
https://www.3dmattermadetoorder.kit.edu/business_breakfast.php

Before, it was all 'confidential' about Ken Sorensen and TheoremRx - no doubt, they were doing the funding rounds.

But the situation has changed.

It seems more public and open. Now he is doing a conference - expect a mention on 201 (being TheoremRx flagship therapy).

"he will present next-generation approaches to drug development..."

Even more exciting!

We normally have an RNS every month. No RNS in April.

There is probably an RNS imminent - my guess is this week IMO. Not sure why people would sell when the news which could lead to a share price rise could just be around the corner.

Exciting week!

RNS should be imminent.

Not much volume today so far.....

@NewParkFarm68
For most, shares are a long-term investment. History tells us that share prices go up over the long term. Hang in there!

We are a life sciences company. Considering mRNA is not "ridiculous".

Yes! RNS due this week as we've not had one in April. But think it's going to be good one!

Interesting! Something for the new lab to integrate or clinical testing partnerships.

Messenger RNA (abbreviated mRNA) is used at BioNTech and now Moderna.

I can't help but think this could have a future at ValiRx.

Price will probably be around 27p-34p until the 201 deal is finalised (or other product developments).
Then 55p+ post deal.

Heading to 35p share by next week.

The plan to open a new lab (or buy/finance an existing lab) is great - bring more things in-house. Revenue generating - TheoremRx - potential client?

If the deadline is end of June for the 201 (prostate cancer) therapy news - when do we think it will come in?

"The potential value of the deal would be in excess of $61 million dollars US plus royalties for the first cancer indication, with 37.5M for each later indication."

Upside - doubling market cap?

OB - Sorry to hear that.
Biotene may help with the lack of saliva problem.

The share price does seem to reduce after the shareholder conferences / Q&As.

There was a talk from the Non Exec Chairman - people may be put off by the term 'Non Exec'.

We need Product-related developments for the share price to move higher.

However, a 33% increase over the past month is not bad!

Presentation was good. Impressed with company direction. Valirx share price increases are always huge!
Not long now!

VAL Market cap 2 years ago = 0.5 million
Today = 19-20 million!
Where next? 40 million market cap?

I didn't catch the Q&A with the CEO. Can anyone let me know what was said (or send me a link to the presentation) please?